Our Take
Phase IIa efficacy for a fully AI-designed drug is a genuine milestone — not a prediction, an actual result. The NVIDIA-Lilly lab could accelerate this further. Drug discovery AI is no longer speculative.
The Insilico Milestone
In February 2026, Insilico Medicine announced that INS018_055 — the first fully AI-designed drug for idiopathic pulmonary fibrosis — completed Phase IIa clinical trials with statistically significant efficacy. The drug compressed what is typically a 12-year discovery timeline to approximately 3 years.
NVIDIA and Lilly Lab
NVIDIA and Eli Lilly announced a co-innovation AI lab focused on creating a continuous learning system that connects agentic wet labs with computational dry labs, enabling 24/7 AI-assisted experimentation to support biologists and chemists.
AlphaFold Integration
AlphaFold 3 is now integrated into virtually every AI drug discovery pipeline, reducing the need for experimental structure determination by an estimated 60-70% — saving months and millions per program.
Regulatory Evolution
The FDA's AI Drug Development Guidance (draft, January 2026) provides a framework for evaluating AI-discovered drugs. A pilot program allows AI-discovered drugs with strong computational evidence to enter Phase I trials with streamlined applications.